<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="phase of about 800 nm. The results of in vivo" exact="tests" post="carried out on rats showed that the oral administration"/>
 <result pre="the permeation test. The results obtained from in vitro release" exact="tests" post="showed that the nanoparticles are characterized by a sustained"/>
 <result pre="index and very high drug loading efficiency (96%). Ex-vivo permeability" exact="tests" post="of drug loaded nanoparticles was carried out using swine"/>
 <result pre="was tested on PC12 cells, as neuronal model cells. These" exact="tests" post="showed that nanoparticles are able to promote drug diffusion"/>
 <result pre="al.’s work regards the therapeutic use of antibodies for the" exact="treatment" post="of neurological diseases [5]. The blood-brain barrier (BBB) is"/>
 <result pre="an example of old drug (antiprotozoal discovered in 1938 for" exact="treatment" post="of Pneumocystis jirovecii pneumonia) characterized by novel properties: recently"/>
 <result pre="and neuroprotective activities in Alzheimer’s disease. Mucoadhesive properties and stability" exact="testing" post="in various environments were evaluated. The progression of Alzheimer’s"/>
 <result pre="gel drug delivery systems designed for nose-to-brain delivery for the" exact="treatment" post="of neurological diseases [11]. In situ-based gels are systems"/>
 <result pre="a non-invasive, efficient, safe, and potentially innovative approach in the" exact="treatment" post="of CNS disorders and brain diseases. Conflicts of Interest"/>
 <result pre="AderibigbeB.A.In situ-based gels for nose to brain delivery for the" exact="treatment" post="of neurological diseasesPharmaceutics2018104010.3390/pharmaceutics1002004029601486 12.DalpiazA.PavanB.Nose-to-brain delivery of antiviral drugs: A"/>
</results>
